Johnson & Johnson complete friendly takeover of Crucell

Feb 22, 2011

Pharmaceutical and health care giant Johnson & Johnson announced Tuesday the successful completion of a friendly takeover of Dutch vaccine maker Crucell, for about 1.75 billion euros ($2.37 billion).

"Johnson & Johnson and Crucell today announce that Johnson & Johnson has completed the tender offer for Crucell," the companies said in a joint statement.

Johnson & Johnson, which employs 114,000 people, has said it intends to retain Crucell's management and staff and to keep the headquarters at Leiden in the western Netherlands.

Johnson & Johnson, which now owns more than 95 percent of Crucell's capital announced a supplementary offer period from Wednesday until March 8.

The health care giant first announced its intention to buy up Crucell last October for 24.75 euros per share.

The European Commission authorised the late last month, seeing no competition problems.

Crucell, which employs 1,300 people, produced more than 115 million doses of vaccine in 2009 for distribution in about 100 countries, mostly developing nations.

Explore further: Booming mobile health app market needs more FDA oversight for consumer safety, confidence

add to favorites email to friend print save as pdf

Related Stories

Johnson & Johnson plans to buy Dutch vaccine group

Sep 17, 2010

US cosmetics and pharmaceutical giant Johnson & Johnson said on Friday it intended to acquire a Dutch vaccine maker Crucell which is active in developing countries for about 1.75 billion euros.

Johnson & Johnson, Crucell biotech announce takeover

Oct 06, 2010

Pharmaceutical and health care giant Johnson & Johnson has reached a deal with Dutch biotechnology vaccine group Crucell to buy 82.5 percent of Crucell for about 1.75 billion euros, the two firms said on Wednesday.

Summer time and the living is breezy

Jun 06, 2006

The U.S. hurricane season is under way and for many people in areas hit hard by 2005's hurricanes, it's going to be an uneasy summer.

Farmers relying on roundup lose some of its benefit

Apr 14, 2009

(PhysOrg.com) -- Roundup Ready crops have made weed control much easier for farmers, but a new study shows their reliance on the technology may be weakening the herbicide's ability to control weeds.

Recommended for you

Determine patient preferences by means of conjoint analysis

7 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

User comments : 0